Halozyme Therapeutics Current Ratio 2006-2021 | HALO

Current and historical current ratio for Halozyme Therapeutics (HALO) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Halozyme Therapeutics current ratio for the three months ending June 30, 2021 was 8.75.
Halozyme Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.00B $0.11B 8.75
2021-03-31 $0.94B $0.11B 8.77
2020-12-31 $0.56B $0.42B 1.32
2020-09-30 $0.50B $0.03B 18.49
2020-06-30 $0.50B $0.03B 19.19
2020-03-31 $0.47B $0.04B 11.14
2019-12-31 $0.54B $0.09B 6.35
2019-09-30 $0.34B $0.11B 3.17
2019-06-30 $0.39B $0.14B 2.89
2019-03-31 $0.41B $0.14B 2.95
2018-12-31 $0.43B $0.15B 2.87
2018-09-30 $0.43B $0.14B 3.09
2018-06-30 $0.46B $0.13B 3.49
2018-03-31 $0.48B $0.12B 4.06
2017-12-31 $0.51B $0.13B 3.89
2017-09-30 $0.35B $0.10B 3.46
2017-06-30 $0.34B $0.08B 4.13
2017-03-31 $0.22B $0.06B 3.60
2016-12-31 $0.26B $0.06B 4.70
2016-09-30 $0.27B $0.05B 5.18
2016-06-30 $0.28B $0.04B 7.31
2016-03-31 $0.30B $0.06B 4.63
2015-12-31 $0.17B $0.06B 2.75
2015-09-30 $0.15B $0.05B 3.41
2015-06-30 $0.17B $0.04B 4.81
2015-03-31 $0.15B $0.03B 5.85
2014-12-31 $0.16B $0.02B 6.63
2014-09-30 $0.16B $0.04B 4.59
2014-06-30 $0.18B $0.03B 5.54
2014-03-31 $0.19B $0.04B 5.25
2013-12-31 $0.10B $0.03B 3.82
2013-09-30 $0.10B $0.04B 2.60
2013-06-30 $0.10B $0.03B 3.06
2013-03-31 $0.11B $0.02B 5.63
2012-12-31 $0.13B $0.02B 6.90
2012-09-30 $0.11B $0.02B 5.02
2012-06-30 $0.12B $0.02B 7.42
2012-03-31 $0.13B $0.02B 7.95
2011-12-31 $0.06B $0.02B 3.70
2011-09-30 $0.08B $0.01B 5.58
2011-06-30 $0.09B $0.03B 2.79
2011-03-31 $0.08B $0.01B 6.28
2010-12-31 $0.09B $0.02B 5.83
2010-09-30 $0.10B $0.01B 8.36
2010-06-30 $0.05B $0.01B 4.46
2010-03-31 $0.06B $0.01B 4.56
2009-12-31 $0.07B $0.01B 5.17
2009-09-30 $0.08B $0.02B 5.27
2009-06-30 $0.09B $0.02B 6.17
2009-03-31 $0.07B $0.01B 4.97
2008-12-31 $0.07B $0.01B 5.21
2008-09-30 $0.08B $0.01B 7.07
2008-06-30 $0.09B $0.01B 9.15
2008-03-31 $0.10B $0.01B 10.06
2007-12-31 $0.10B $0.01B 11.41
2007-09-30 $0.11B $0.01B 13.08
2007-06-30 $0.10B $0.01B 17.15
2007-03-31 $0.07B $0.01B 14.22
2006-12-31 $0.05B $0.00B 10.73
2006-09-30 $0.02B $0.00B 6.29
2006-06-30 $0.02B $0.00B 6.78
2006-03-31 $0.02B $0.00B 6.90
2005-12-31 $0.02B $0.00B 8.73
2005-09-30 $0.01B $0.00B 3.83
2005-06-30 $0.01B $0.00B 6.15
2005-03-31 $0.01B $0.00B 7.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.533B $0.268B
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76